Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Acquires Phase III Antibiotic Via Peninsula Purchase

This article was originally published in The Pink Sheet Daily

Executive Summary

Johnson & Johnson is acquiring the Phase III injectable carbapenem antibiotic doripenem via the $245 mil. acquisition of Peninsula Pharmaceuticals

You may also be interested in...



Ortho-McNeil Gets FDA Approval For Complicated Intra-Abdominal/UTI Therapy Doribax

Studies of the novel injectable carbapenem antibiotic showed activity in several forms of Gram-positive and Gram-negative bacteria, including Pseudomonas.

Ortho-McNeil Gets FDA Approval For Complicated Intra-Abdominal/UTI Therapy Doribax

Studies of the novel injectable carbapenem antibiotic showed activity in several forms of Gram-positive and Gram-negative bacteria, including Pseudomonas.

J&J Submits NDA For Novel Antibiotic Doripenem

Drug could reach market by October 2007.

Related Content

Topics

UsernamePublicRestriction

Register

PS062018

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel